Working… Menu
Trial record 1 of 2 for:    NCT03525613
Previous Study | Return to List | Next Study

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03525613
Recruitment Status : Active, not recruiting
First Posted : May 15, 2018
Last Update Posted : June 21, 2021
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 30, 2021
Estimated Study Completion Date : January 30, 2023